Ionis Historical Cash Flow

IONS Stock

USD 35.90 0.53 1.50%

Analysis of Ionis Pharmaceuticals cash flow over time is an excellent tool to project Ionis Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 533.1 M or Depreciation of 23.6 M as it is a great indicator of Ionis Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Ionis Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ionis Pharmaceuticals is a good buy for the upcoming year.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.

About Ionis Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Ionis balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Ionis's non-liquid assets can be easily converted into cash.

Ionis Pharmaceuticals Cash Flow Chart

At this time, Ionis Pharmaceuticals' Investments are comparatively stable compared to the past year. Change Receivables is likely to gain to about 42.6 M in 2024, despite the fact that Change In Working Capital is likely to grow to (73.4 M).

Begin Period Cash Flow Capital Expenditures End Period Cash Flow Stock Based Compensation Change To Netincome Issuance Of Capital Stock

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by Ionis Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Ionis Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Most accounts from Ionis Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Ionis Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.At this time, Ionis Pharmaceuticals' Investments are comparatively stable compared to the past year. Change Receivables is likely to gain to about 42.6 M in 2024, despite the fact that Change In Working Capital is likely to grow to (73.4 M).

Ionis Pharmaceuticals cash flow statement Correlations

	Change In Cash	Free Cash Flow	Change In Working Capital	Begin Period Cash Flow	Depreciation	Other Non Cash Items	Capital Expenditures	Net Income	End Period Cash Flow	Change To Account Receivables	Change To Liabilities	Stock Based Compensation	Change To Inventory	Sale Purchase Of Stock	Investments	Change Receivables	Net Borrowings	Cash And Cash Equivalents Changes	Cash Flows Other Operating	Change To Netincome	Change To Operating Activities	Issuance Of Capital Stock	Exchange Rate Changes
Change In Cash		0.4	-0.06	-0.54	-0.05	0.65	0.02	0.55	0.51	-0.28	-0.16	-0.04	-0.47	0.13	0.05	0.11	0.22	0.69	0.13	-0.25	-0.61	0.01	0.01
Free Cash Flow	0.4		0.62	-0.27	-0.4	0.52	0.04	0.78	0.09	0.27	-0.2	0.24	0.17	0.67	-0.58	0.16	0.26	0.72	0.73	-0.27	-0.77	0.41	0.59
Change In Working Capital	-0.06	0.62		-0.2	-0.23	0.02	-0.22	0.34	-0.29	0.41	0.16	-0.04	0.34	0.87	-0.88	0.2	-0.02	0.09	0.86	-0.57	-0.42	0.42	0.25
Begin Period Cash Flow	-0.54	-0.27	-0.2		0.64	-0.59	0.45	-0.47	0.43	0.18	0.1	0.66	0.36	-0.35	0.15	0.4	0.33	-0.39	-0.39	0.63	0.39	-0.72	-0.49
Depreciation	-0.05	-0.4	-0.23	0.64		-0.35	0.54	-0.48	0.66	-0.27	0.3	0.51	0.11	-0.29	0.14	0.51	0.13	-0.43	-0.44	0.36	0.35	-0.89	-0.82
Other Non Cash Items	0.65	0.52	0.02	-0.59	-0.35		0.18	0.35	0.07	-0.43	-0.22	0.14	-0.26	0.22	0.05	-0.17	0.2	0.55	0.32	0.06	-0.36	0.34	0.56
Capital Expenditures	0.02	0.04	-0.22	0.45	0.54	0.18		-0.25	0.51	-0.25	0.15	0.79	-0.06	-0.1	0.08	0.59	0.23	-0.18	-0.32	0.65	0.12	-0.61	-0.23
Net Income	0.55	0.78	0.34	-0.47	-0.48	0.35	-0.25		0.05	0.22	-0.24	-0.18	0.01	0.48	-0.47	-0.08	-0.07	0.81	0.48	-0.58	-0.86	0.49	0.47
End Period Cash Flow	0.51	0.09	-0.29	0.43	0.66	0.07	0.51	0.05		-0.17	-0.02	0.62	-0.16	-0.24	0.22	0.56	0.54	0.27	-0.29	0.38	-0.19	-0.78	-0.55
Change To Account Receivables	-0.28	0.27	0.41	0.18	-0.27	-0.43	-0.25	0.22	-0.17		-0.01	-0.18	0.36	0.27	-0.31	0.34	0.23	0.21	0.24	-0.21	-0.35	0.25	0.14
Change To Liabilities	-0.16	-0.2	0.16	0.1	0.3	-0.22	0.15	-0.24	-0.02	-0.01		-0.1	-0.13	0.16	-0.28	0.37	-0.46	-0.46	-0.29	-0.06	0.29	-0.23	-0.3
Stock Based Compensation	-0.04	0.24	-0.04	0.66	0.51	0.14	0.79	-0.18	0.62	-0.18	-0.1		0.16	-0.07	0.03	0.47	0.55	-0.03	-0.04	0.69	0.04	-0.61	-0.18
Change To Inventory	-0.47	0.17	0.34	0.36	0.11	-0.26	-0.06	0.01	-0.16	0.36	-0.13	0.16		0.28	-0.37	-0.14	0.14	-0.01	0.32	-0.09	-0.1	0.17	0.12
Sale Purchase Of Stock	0.13	0.67	0.87	-0.35	-0.29	0.22	-0.1	0.48	-0.24	0.27	0.16	-0.07	0.28		-0.91	0.08	-0.06	0.25	0.8	-0.6	-0.59	0.48	0.29
Investments	0.05	-0.58	-0.88	0.15	0.14	0.05	0.08	-0.47	0.22	-0.31	-0.28	0.03	-0.37	-0.91		-0.18	0.26	-0.07	-0.69	0.64	0.49	-0.34	-0.15
Change Receivables	0.11	0.16	0.2	0.4	0.51	-0.17	0.59	-0.08	0.56	0.34	0.37	0.47	-0.14	0.08	-0.18		0.27	-0.09	-0.11	0.22	-0.1	-0.58	-0.42
Net Borrowings	0.22	0.26	-0.02	0.33	0.13	0.2	0.23	-0.07	0.54	0.23	-0.46	0.55	0.14	-0.06	0.26	0.27		0.42	0.17	0.46	-0.26	-0.26	-0.07
Cash And Cash Equivalents Changes	0.69	0.72	0.09	-0.39	-0.43	0.55	-0.18	0.81	0.27	0.21	-0.46	-0.03	-0.01	0.25	-0.07	-0.09	0.42		0.38	-0.23	-0.84	0.38	0.46
Cash Flows Other Operating	0.13	0.73	0.86	-0.39	-0.44	0.32	-0.32	0.48	-0.29	0.24	-0.29	-0.04	0.32	0.8	-0.69	-0.11	0.17	0.38		-0.53	-0.54	0.6	0.49
Change To Netincome	-0.25	-0.27	-0.57	0.63	0.36	0.06	0.65	-0.58	0.38	-0.21	-0.06	0.69	-0.09	-0.6	0.64	0.22	0.46	-0.23	-0.53		0.51	-0.59	-0.12
Change To Operating Activities	-0.61	-0.77	-0.42	0.39	0.35	-0.36	0.12	-0.86	-0.19	-0.35	0.29	0.04	-0.1	-0.59	0.49	-0.1	-0.26	-0.84	-0.54	0.51		-0.39	-0.28
Issuance Of Capital Stock	0.01	0.41	0.42	-0.72	-0.89	0.34	-0.61	0.49	-0.78	0.25	-0.23	-0.61	0.17	0.48	-0.34	-0.58	-0.26	0.38	0.6	-0.59	-0.39		0.8
Exchange Rate Changes	0.01	0.59	0.25	-0.49	-0.82	0.56	-0.23	0.47	-0.55	0.14	-0.3	-0.18	0.12	0.29	-0.15	-0.42	-0.07	0.46	0.49	-0.12	-0.28	0.8

Click cells to compare fundamentals

Ionis Pharmaceuticals Account Relationship Matchups

Ionis Pharmaceuticals cash flow statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Change In Cash	404.5M	(285.6M)	471.5M	(592.7M)	122.8M	128.9M
Free Cash Flow	309.4M	(5.2M)	12.9M	(294.5M)	(335.5M)	(318.7M)
Change In Working Capital	(168.7M)	(73.6M)	(113.8M)	7.6M	(77.3M)	(73.4M)
Begin Period Cash Flow	278.8M	683.3M	397.7M	869.2M	276.5M	154.8M
Other Cashflows From Financing Activities	203.3M	(558.1M)	(79.2M)	(11.0M)	507.7M	533.1M
Depreciation	16.0M	17.2M	19.6M	22.1M	22.5M	23.6M
Other Non Cash Items	55.7M	35.7M	7.7M	(134.6M)	7.7M	8.1M
Capital Expenditures	36.3M	41.0M	17.9M	20.1M	28.0M	29.4M
Total Cash From Operating Activities	345.7M	35.9M	30.8M	(274.4M)	(307.5M)	(292.1M)
Net Income	303.3M	(486.8M)	(28.6M)	(269.7M)	(366.3M)	(348.0M)
Total Cash From Financing Activities	100.0M	(596.6M)	245.9M	(55.3M)	644.1M	676.3M
End Period Cash Flow	683.3M	397.7M	869.2M	276.5M	399.3M	419.2M
Change To Account Receivables	(44.2M)	(22M)	5.1M	36.4M	(72.1M)	(68.5M)
Change To Liabilities	23.4M	(5.7M)	(42.6M)	64.4M	74.0M	77.7M
Stock Based Compensation	146.6M	230.1M	120.7M	100.3M	105.8M	58.6M
Change To Inventory	(5.4M)	(1.3M)	(2.8M)	2.8M	(6.4M)	(6.1M)
Total Cashflows From Investing Activities	(41.3M)	274.5M	194.9M	(262.6M)	(236.4M)	(224.6M)
Sale Purchase Of Stock	(34.4M)	(90.5M)	(16.7M)	(11.0M)	(9.9M)	(9.4M)
Investments	(5.0M)	315.5M	212.8M	(262.6M)	24.7M	26.0M
Net Borrowings	(22.1M)	313.6M	418.3M	(50.7M)	(58.3M)	(55.4M)
Cash And Cash Equivalents Changes	404.5M	(285.6M)	471.5M	(592.3M)	(533.1M)	(506.4M)
Cash Flows Other Operating	(183.1M)	(64.9M)	(66.7M)	(204.3M)	(183.9M)	(174.7M)
Other Cashflows From Investing Activities	(5.4M)	(5.9M)	(5.9M)	249.7M	287.2M	301.5M
Change To Netincome	161.3M	528.8M	130.9M	103.0M	118.5M	87.2M
Change To Operating Activities	(20.1M)	50.8M	(36.2M)	32.4M	37.2M	39.1M
Issuance Of Capital Stock	119.7M	52.0M	11.6M	6.4M	9.0M	8.6M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Ionis Stock Analysis

When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ionis Historical Cash Flow

About Ionis Cash Flow Analysis

Ionis Pharmaceuticals Cash Flow Chart

Begin Period Cash Flow

Capital Expenditures

Stock Based Compensation

Ionis Pharmaceuticals cash flow statement Correlations

Ionis Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ionis Pharmaceuticals cash flow statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Ionis Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Sale Purchase Of Stock	+ 0.87	Change In Working Capital
Cash Flows Other Operating	+ 0.86	Change In Working Capital
Cash And Cash Equivalents Changes	+ 0.81	Net Income
Cash Flows Other Operating	+ 0.8	Sale Purchase Of Stock
Exchange Rate Changes	+ 0.8	Issuance Of Capital Stock
Stock Based Compensation	+ 0.79	Capital Expenditures

Investments	- 0.91	Sale Purchase Of Stock
Issuance Of Capital Stock	- 0.89	Depreciation
Investments	- 0.88	Change In Working Capital
Change To Operating Activities	- 0.86	Net Income
Change To Operating Activities	- 0.84	Cash And Cash Equivalents Changes
Exchange Rate Changes	- 0.82	Depreciation